We are live on ! Find out more
PCM

Prelude Capital Management Portfolio holdings

AUM $1.31B
1-Year Est. Return 62.02%
This Fund
S&P 500
This Quarter Est. Return
+9.53%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.36B
AUM Growth
+$77.6M
Cap. Flow
+$46.1M
Cap. Flow %
3.39%
Top 10 Hldgs %
13.88%
Holding
1,633
New
514
Increased
325
Reduced
386
Closed
373

Top Buys

Rank Stock Value
1
NICE icon
Nice
NICE
+$14.2M
2
DOMO icon
Domo
DOMO
+$12.7M
3
NFLX icon
Netflix
NFLX
+$12.4M
4
EA
Electronic Arts
EA
+$12.3M
5
DAY
Dayforce
DAY
+$11.5M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$17.1M
2
COOP
Mr. Cooper
COOP
+$13.5M
3
K
Kellanova
K
+$11.9M
4
LITE icon
Lumentum
LITE
+$9.69M
5
IBIT icon
iShares Bitcoin Trust
IBIT
+$9.44M

Sector Composition

Rank Sector Weight
1 Technology 23.27%
2 Healthcare 13.54%
3 Communication Services 10.55%
4 Consumer Discretionary 9.61%
5 Industrials 9.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANNX icon
1226
Annexon
ANNX
$883M
$60.2K ﹤0.01%
+12,000
New +$45.9K
OMSE
1227
OMS Energy Technologies
OMSE
$191M
$60K ﹤0.01%
+13,628
New +$63.8K
GDRX icon
1228
GoodRx Holdings
GDRX
$1.25B
$59.9K ﹤0.01%
22,100
+5,900
+36% +$19.4K
EGHT icon
1229
8x8 Inc
EGHT
$324M
$59.8K ﹤0.01%
30,365
+18,200
+150% +$35.8K
JBLU icon
1230
JetBlue
JBLU
$2.13B
$59K ﹤0.01%
+12,969
New +$59.1K
SRI icon
1231
Stoneridge
SRI
$203M
$58.2K ﹤0.01%
+10,050
New +$63.2K
CDXS icon
1232
Codexis
CDXS
$161M
$56.7K ﹤0.01%
34,787
-1,140
-3% -$2.33K
EXFY icon
1233
Expensify
EXFY
$225M
$55K ﹤0.01%
36,400
– –
CMPX icon
1234
Compass Therapeutics
CMPX
$400M
$53.7K ﹤0.01%
+10,000
New +$46.2K
DH icon
1235
Definitive Healthcare
DH
$73.7M
$48.8K ﹤0.01%
17,000
+1,300
+8% +$3.6K
KOPN icon
1236
Kopin
KOPN
$780M
$48.5K ﹤0.01%
+20,748
New +$59.9K
SVCO
1237
Silvaco Group
SVCO
$247M
$48.2K ﹤0.01%
+11,900
New +$59.1K
BIVIW
1238
BioVie Inc Warrant
BIVIW
$64K
$48K ﹤0.01%
186,621
-106,815
-36% -$35K
ARTV
1239
Artiva Biotherapeutics
ARTV
$549M
$45.9K ﹤0.01%
10,691
-3,611
-25% -$13.6K
AGEN
1240
Agenus
AGEN
$291M
$45.5K ﹤0.01%
+14,500
New +$57.7K
WHWK
1241
Whitehawk Therapeutics
WHWK
$259M
$45.5K ﹤0.01%
+18,796
New +$43.1K
CATO icon
1242
Cato Corp
CATO
$66.3M
$45.1K ﹤0.01%
+14,589
New +$53.6K
GAU
1243
Galiano Gold
GAU
$522M
$42.6K ﹤0.01%
+16,832
New +$41.6K
LRMR icon
1244
Larimar Therapeutics
LRMR
$417M
$41.4K ﹤0.01%
10,867
– –
RXRX icon
1245
Recursion Pharmaceuticals
RXRX
$1.76B
$40.9K ﹤0.01%
+10,000
New +$49.5K
PLX icon
1246
Protalix BioTherapeutics
PLX
$200M
$40K ﹤0.01%
22,243
-27,548
-55% -$56.3K
COTY icon
1247
Coty
COTY
$2.51B
$38K ﹤0.01%
12,323
-30,084
-71% -$109K
PRME icon
1248
Prime Medicine
PRME
$571M
$35.4K ﹤0.01%
10,200
-12,283
-55% -$54.6K
ABSI icon
1249
Absci
ABSI
$1.53B
$34.9K ﹤0.01%
+10,000
New +$36.4K
ALTO icon
1250
Alto Ingredients
ALTO
$328M
$32K ﹤0.01%
+11,100
New +$20.9K
48 49
50
51 52

Similar funds

PFBT
Parkside Financial Bank & Trust Saint Louis, Missouri $1.31B AUM 19.14% 1-Year Est. Return
CCP
Clarkston Capital Partners Rochester, Michigan $1.31B AUM 3.79% 1-Year Est. Return
SP
Sherman Porfolios Coeur D'alene, Idaho $1.3B AUM 35.18% 1-Year Est. Return
HCS
Himension Capital (Singapore) Singapore $1.3B AUM 85.53% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
GPCM
Greenbrier Partners Capital Management Dallas, Texas $1.3B AUM 21.43% 1-Year Est. Return
MCM
Mainstay Capital Management Grand Blanc, Michigan $1.3B AUM 37.8% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Prelude Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Prelude Capital Management held 1,633 positions worth $1.36B, up 6.1% from $1.28B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Prelude Capital Management deployed $46.1M of net new capital in Q4 2025, opening 514 new positions and adding to 325 existing holdings. Its largest new stake was Nice: 117,600 shares worth $13.3M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Communication Services.

On the sell side, the largest reduction was Lumentum, an estimated $9.69M trimmed.

  • Prelude Capital Management's largest Q4 2025 buy was Nice: 117,600 shares worth $13.3M.
  • Prelude Capital Management added most to Domo in Q4 2025, an estimated $12.7M increase.
  • Prelude Capital Management's biggest Q4 2025 reduction was Lumentum, cutting an estimated $9.69M.
  • Prelude Capital Management fully exited Verona Pharma in Q4 2025, selling an estimated $17.1M.
  • Prelude Capital Management's ten largest holdings make up 14% of its $1.36B portfolio in Q4 2025.
  • Prelude Capital Management opened 514 new positions and closed 373 in Q4 2025.
  • Prelude Capital Management's portfolio value rose 6.1% quarter-over-quarter to $1.36B.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.